Literature DB >> 30243546

Addressing New Diagnostic and Treatment Challenges Associated With a New Age of Cancer Treatment.

Jason J Bischof1, Carolyn J Presley2, Jeffrey M Caterino3.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 30243546      PMCID： PMC6377798          DOI： 10.1016/j.annemergmed.2018.08.421

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN： 0196-0644            Impact factor:   5.721


× No keyword cloud information.
  21 in total

1.  Cancer Immunotherapy: An Evidence-Based Overview and Implications for Practice.

Authors:  Virginia Bayer; Beau Amaya; Diane Baniewicz; Colleen Callahan; Lisa Marsh; Asia S McCoy
Journal:  Clin J Oncol Nurs       Date:  2017-04-01       Impact factor: 1.027

2.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

3.  The Emergency Care of Patients With Cancer: Setting the Research Agenda.

Authors:  Jeremy Brown; Corita Grudzen; Demetrios N Kyriacou; Ziad Obermeyer; Tammie Quest; Donna Rivera; Susan Stone; Jason Wright; Nonniekaye Shelburne
Journal:  Ann Emerg Med       Date:  2016-02-26       Impact factor: 5.721

Review 4.  Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment.

Authors:  Mark A Lewis; Andrea Wahner Hendrickson; Timothy J Moynihan
Journal:  CA Cancer J Clin       Date:  2011-08-19       Impact factor: 508.702

5.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

Review 6.  Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.

Authors:  A K S Salama; S J Moschos
Journal:  Ann Oncol       Date:  2017-01-01       Impact factor: 32.976

Review 7.  Immune-related Adverse Events in Cancer Patients.

Authors:  Daniel J Pallin; Christopher W Baugh; Michael A Postow; Jeffrey M Caterino; Timothy B Erickson; Gary H Lyman
Journal:  Acad Emerg Med       Date:  2018-05-25       Impact factor: 3.451

Review 8.  Emerging targets in cancer immunotherapy.

Authors:  Samantha Burugu; Amanda R Dancsok; Torsten O Nielsen
Journal:  Semin Cancer Biol       Date:  2017-10-05       Impact factor: 15.707

Review 9.  The Most Recent Oncologic Emergency: What Emergency Physicians Need to Know About the Potential Complications of Immune Checkpoint Inhibitors.

Authors:  Duncan Simmons; Eddy Lang
Journal:  Cureus       Date:  2017-10-13

Review 10.  Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer.

Authors:  Jennifer Dine; RuthAnn Gordon; Yelena Shames; Mary Kate Kasler; Margaret Barton-Burke
Journal:  Asia Pac J Oncol Nurs       Date:  2017 Apr-Jun
View more
  1 in total

1.  Emergency Department Utilization for Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis of Identification and Outcomes for Those Presenting for Immune-Related Adverse Events.

Authors:  Ryan Holstead; Adi Kartolo; Tara Baetz
Journal:  Curr Oncol       Date:  2020-12-02       Impact factor: 3.677
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.